Johnson & Johnson $JNJ Shares Bought by Calamos Wealth Management LLC

Calamos Wealth Management LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 3.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 120,131 shares of the company’s stock after acquiring an additional 3,737 shares during the period. Johnson & Johnson comprises approximately 0.8% of Calamos Wealth Management LLC’s holdings, making the stock its 24th largest position. Calamos Wealth Management LLC’s holdings in Johnson & Johnson were worth $18,350,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Ellis Investment Partners LLC increased its position in shares of Johnson & Johnson by 0.7% in the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after acquiring an additional 62 shares in the last quarter. Cypress Wealth Services LLC increased its position in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock worth $1,013,000 after acquiring an additional 62 shares in the last quarter. Horizon Bancorp Inc. IN increased its position in shares of Johnson & Johnson by 11.2% in the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock worth $97,000 after acquiring an additional 64 shares in the last quarter. Global Strategic Investment Solutions LLC increased its position in shares of Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after acquiring an additional 65 shares in the last quarter. Finally, JSF Financial LLC increased its position in shares of Johnson & Johnson by 2.2% in the second quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock worth $457,000 after acquiring an additional 65 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

NYSE JNJ opened at $193.78 on Tuesday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $466.68 billion, a PE ratio of 18.70, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a 50 day moving average price of $180.89 and a two-hundred day moving average price of $165.18. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s payout ratio is 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently commented on JNJ shares. Raymond James Financial raised their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. UBS Group raised their price target on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Finally, Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $200.06.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.